Regeneron Pharmaceuticals Inc is experiencing a notable uptick in its stock price, driven by positive clinical trial results and a favorable market outlook.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is rising today, up 1.50% to close at CA$764.43. This upward movement follows the announcement of encouraging results from its clinical trials and ongoing positive sentiment in the biotech sector.
Investor takeaway: Investors are optimistic about Regeneron's future prospects, especially with the recent positive data from its Pasatru™ clinical trials, which could enhance its market position in the rare disease treatment space.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$78.54B
P/E
19.3x
Div. yield
0.49%
Div. / share
$3.64
52W high
$859.34
52W low
$561.12
1W change
+1.95%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 14, 2026
Wall Street analysts forecast REGN stock price to rise 14.2% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$859.69
+14.2% Upside
Previously C$859.04 on Oct 12, 2026
Current Price
C$753.12
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.9%
Annualized
90-Day Vol
29.4%
Annualized
Trend (90d)
+48.3%
Annualized drift
90d Mean
C$894.79
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$797.66 | C$721.99 – C$881.26 |
| 60 trading days | C$844.83 | C$733.76 – C$972.71 |
| 90 trading days | C$894.79 | C$752.92 – C$1063.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.50% Gain in Stock Price
Regeneron’s stock price increase reflects investor confidence following positive trial results and a favorable outlook for the biotechnology sector.
Bull case
The successful results from the OPTIMA trial for Pasatru™ show that the drug could significantly improve patient outcomes in fibrodysplasia ossificans progressiva (FOP). This success could lead to increased sales and a larger market share.
Bear case
Despite today's gains, the biotech sector remains volatile. Any setbacks in upcoming trials or regulatory approvals could negatively impact Regeneron's stock performance.
Advertisement
Positive Clinical Trial Results
Regeneron's recent announcement about the OPTIMA trial results for Pasatru™ has significantly contributed to the stock's rise. The drug has demonstrated promising efficacy in treating fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. The data indicates a sustained reduction in new heterotopic ossification lesions, which is a critical outcome for patients suffering from this debilitating condition.
Market Sentiment and Future Outlook
The overall sentiment in the biotech sector has been improving, with analysts predicting a potential wave of mergers and acquisitions that could further boost stocks like Regeneron. Investors are closely watching the upcoming earnings report scheduled for October 30, 2026, where Regeneron is expected to maintain its streak of beating earnings estimates, adding to the bullish sentiment surrounding the stock.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
